ATE250602T1 - Pyrimido(6,1-a)isochinolinonderivate - Google Patents

Pyrimido(6,1-a)isochinolinonderivate

Info

Publication number
ATE250602T1
ATE250602T1 AT00920857T AT00920857T ATE250602T1 AT E250602 T1 ATE250602 T1 AT E250602T1 AT 00920857 T AT00920857 T AT 00920857T AT 00920857 T AT00920857 T AT 00920857T AT E250602 T1 ATE250602 T1 AT E250602T1
Authority
AT
Austria
Prior art keywords
pyrimido
derivatives
isochinolinone
isoquinolin
relates
Prior art date
Application number
AT00920857T
Other languages
English (en)
Inventor
Alexander William Oxford
David Jack
Original Assignee
Vernalis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9907454.4A external-priority patent/GB9907454D0/en
Priority claimed from GBGB9909802.2A external-priority patent/GB9909802D0/en
Application filed by Vernalis Ltd filed Critical Vernalis Ltd
Application granted granted Critical
Publication of ATE250602T1 publication Critical patent/ATE250602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT00920857T 1999-03-31 2000-03-29 Pyrimido(6,1-a)isochinolinonderivate ATE250602T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9907454.4A GB9907454D0 (en) 1999-03-31 1999-03-31 Compounds
GBGB9909802.2A GB9909802D0 (en) 1999-04-28 1999-04-28 Compounds
PCT/GB2000/001193 WO2000058308A1 (en) 1999-03-31 2000-03-29 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE

Publications (1)

Publication Number Publication Date
ATE250602T1 true ATE250602T1 (de) 2003-10-15

Family

ID=26315369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920857T ATE250602T1 (de) 1999-03-31 2000-03-29 Pyrimido(6,1-a)isochinolinonderivate

Country Status (16)

Country Link
US (5) US6794391B2 (de)
EP (1) EP1165558B1 (de)
JP (1) JP4685243B2 (de)
CN (1) CN100415743C (de)
AT (1) ATE250602T1 (de)
AU (1) AU773504B2 (de)
BR (1) BRPI0009446B8 (de)
CA (1) CA2368413C (de)
DE (1) DE60005493T2 (de)
DK (1) DK1165558T3 (de)
ES (1) ES2208310T3 (de)
MX (1) MXPA01009846A (de)
NO (1) NO20014728L (de)
NZ (1) NZ514158A (de)
PT (1) PT1165558E (de)
WO (1) WO2000058308A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4685243B2 (ja) * 1999-03-31 2011-05-18 ベローナ・ファーマ・ピーエルシー ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
EP1898894A1 (de) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp-iv-hemmer zur behandlung von atemwegserkrankungen
EP2138495A1 (de) * 2008-06-26 2009-12-30 sanofi-aventis Substituierte Pyrimido[2,1-a]isochinolin-4-on-Derivate
PT2603509E (pt) * 2010-08-09 2014-08-29 Verona Pharma Plc Forma cristalina de um composto pirimidio[6,1-a]isoquinolin-4-ona
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
ES2666098T3 (es) 2013-03-15 2018-05-03 Verona Pharma Plc Combinación de fármacos
US10864213B2 (en) * 2014-05-12 2020-12-15 Verona Pharma Plc Treatment
NO3193835T3 (de) 2014-09-15 2018-08-04
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201613054D0 (en) * 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
IL280075B2 (en) 2018-07-13 2024-06-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A conjugated tricyclic compound as a dual PDE3/PDE4 inhibitor
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
CN114929701A (zh) * 2020-01-15 2022-08-19 正大天晴药业集团股份有限公司 一种pde3/pde4双重抑制剂的结晶及其应用
US20230060174A1 (en) * 2020-01-15 2023-03-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
KR20240004495A (ko) 2021-04-29 2024-01-11 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 이소퀴놀론 화합물과 이의 용도
EP4423085A1 (de) 2021-10-29 2024-09-04 Teva Pharmaceuticals International GmbH Feste formen von ensifentrin und verfahren zu ihrer herstellung
TW202325301A (zh) 2021-12-14 2023-07-01 大陸商海思科醫藥集團股份有限公司 三環稠雜環類pde3/4雙重抑制及其用途
CN118510779A (zh) 2022-01-21 2024-08-16 西藏海思科制药有限公司 三环稠杂环类pde3/4双重抑制及其用途
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024033624A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)
WO2024033627A1 (en) 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
WO2024084212A1 (en) 2022-10-20 2024-04-25 Verona Pharma Plc Treatment of idiopatic pulmonary fibrosis with ensifentrine
WO2024088402A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种异喹啉酮类化合物的晶型及其制备方法
EP4378942A1 (de) 2022-12-02 2024-06-05 Sandoz AG Kristalline form eines pde3/4 inhibitors
WO2024127413A1 (en) * 2022-12-14 2024-06-20 Cipla Limited Solid state forms of ensifentrine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ185900A (en) * 1976-12-10 1981-04-24 Hoechst Ag Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines
FI64370C (fi) * 1977-05-05 1983-11-10 Hoechst Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4307092A (en) * 1979-08-13 1981-12-22 Ayerst Mckenna & Harrison, Inc. 1-Oxo-5H-pyrimido[2,1-C]benzoxazine-2-carboxylic acid esters
US4254118A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1-Oxo-5H-pyrimido[2,1-c][1,4]benzthiazine-2-carboxylic acid esters
US4254121A (en) * 1979-08-13 1981-03-03 Ayerst, Mckenna & Harrison Inc. 3-Oxo-5H-pyrimido[2,1-c][1,4 ]benzoxazines
ZW6284A1 (en) * 1983-05-05 1985-10-30 Hoffmann La Roche Novel pyrimidone derivatives
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
DE3816995A1 (de) * 1988-05-19 1989-11-23 Hoechst Ag Verwendung von pyrimido-(6,1-a)-isochinolin-4-on-derivaten und medizinische zubereitungen auf basis dieser verbindungen
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10287655A (ja) * 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
JP4685243B2 (ja) * 1999-03-31 2011-05-18 ベローナ・ファーマ・ピーエルシー ピリミド［６，１−ａ］イソキノリン−４−オン誘導体

Also Published As

Publication number Publication date
BRPI0009446B1 (pt) 2016-11-01
DE60005493T2 (de) 2004-07-01
US6794391B2 (en) 2004-09-21
DE60005493D1 (de) 2003-10-30
MXPA01009846A (es) 2003-06-24
JP2002540207A (ja) 2002-11-26
BR0009446A (pt) 2002-01-15
CN100415743C (zh) 2008-09-03
WO2000058308A1 (en) 2000-10-05
EP1165558B1 (de) 2003-09-24
CA2368413C (en) 2008-07-29
US20030036542A1 (en) 2003-02-20
AU773504B2 (en) 2004-05-27
US7378424B2 (en) 2008-05-27
US7105663B2 (en) 2006-09-12
JP4685243B2 (ja) 2011-05-18
US20040176353A1 (en) 2004-09-09
BRPI0009446B8 (pt) 2021-05-25
US20080206163A1 (en) 2008-08-28
NO20014728L (no) 2001-11-23
PT1165558E (pt) 2004-02-27
NZ514158A (en) 2000-03-29
US20120302533A1 (en) 2012-11-29
DK1165558T3 (da) 2004-02-09
ES2208310T3 (es) 2004-06-16
AU4127400A (en) 2000-10-16
CN1348453A (zh) 2002-05-08
US20040171828A1 (en) 2004-09-02
EP1165558A1 (de) 2002-01-02
NO20014728D0 (no) 2001-09-28
CA2368413A1 (en) 2000-10-05
US8242127B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
DE60005493D1 (de) Pyrimido[6,1-a]isochinolinonderivate
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
WO2001049688A8 (en) Purine derivatives, process for their preparation and use thereof
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MY134589A (en) Imidazopyrazines as cyclin dependent kinase inhibitors
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
FI945363A (fi) Uusia merkaptoasetyyliamidopyridatso (1,2)pyridatsiini-, pyratsolo(1,2)pyridatsiini-, pyridatso (1,2-a)(1,2)diatsepiini- ja pyratsolo(1,2-a)(1,2)diatsepiinijohdannaisia, jotka ovat käyttökelpoisia enkefalisaasin ja ACE:n estäjinä
MY141978A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
HK1065483A1 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2004026310A8 (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO1997015555A3 (de) Imidazolderivate und deren verwendung als stickstoffmonoxid-synthase-inhibitoren
MY136840A (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals
MY136822A (en) Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
ATE259813T1 (de) Triazolopyrimidinderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165558

Country of ref document: EP

REN Ceased due to non-payment of the annual fee